BPC 157 / TB-500 Capsule (500mcg / 500mcg)

BPC-157 and TB-500 Capsule (500mcg/500mcg) — Research Overview

BPC-157 and TB-500 (500mcg/500mcg) is a research-grade dual-peptide formulation combining two of the most studied synthetic peptides in preclinical connective tissue and cellular migration research. The capsule format delivers both compounds in a single consistent unit dose.

What the Research Shows

BPC-157 is a synthetic 15-amino-acid peptide with over 100 preclinical studies. Its most consistently documented mechanism involves VEGFR2 activation and Akt-eNOS signaling, promoting angiogenesis in connective tissue research models (Hsieh et al., Journal of Molecular Medicine, 2017, DOI: 10.1007/s00109-016-1488-y).

TB-500 is a synthetic Thymosin Beta-4 analog whose primary mechanism involves actin polymerization and cytoskeletal dynamics driving cell migration. Research in the Annals of the New York Academy of Sciences documented Thymosin Beta-4’s role in cell migration and angiogenesis (PMID: 17084833).

The research rationale for studying the two together is mechanistic complementarity. BPC-157 addresses vascular formation through the VEGFR2 pathway while TB-500 addresses cellular migration through cytoskeletal dynamics — distinct pathways with minimal overlap. Neither compound is approved by the FDA for human or veterinary therapeutic use. BPC-157 human data consists of three small studies totaling fewer than 30 participants. No human clinical trials exist for TB-500.

Quality Documentation

• 99%+ purity — HPLC and Mass Spectrometry verified
• BPC-157 500mcg + TB-500 500mcg per capsule
• Batch-specific COA included with every order
• USA tested and fulfilled

Read the BPC-157 and TB-500 research overview

For laboratory research purposes only. Not for human or veterinary consumption.